Disposable Prefilled Syringes Market: as GLP-1 agonist commercial scale-up compels Novo Nordisk and Eli Lilly to expand injectable manufacturing capacity by over one-third, container manufacturers are racing to reshore glass and polymer syringe production, so US capacity investment is compounding on top of underlying demand growth, while oral GLP-1 development creates a mid-horizon substitution risk the container supply chain has not yet priced in.

The global disposable prefilled syringes market size was USD 9.62 Billion in 2025 and is expected to register a revenue CAGR of 9.0% during the forecast period.Market revenue growth is driven by factors such as the commercial expansion of GLP-1 receptor agonist therapies, accelerating biosimilar launch volumes, and the reshoring of glass and polymer syringe manufacturing capacity to the United States.The first driving factor is the commercial expansion of GLP-1 receptor agonist therapies including semaglutide and tirzepatide, which generated an estimated USD 50 Billion in combined global sales in 2025.Novo Nordisk and Eli Lilly have both reported manufacturing capacity expansions of over one-third for prefilled syringe and pen device production, with Gerresheimer's Plastics and Devices division recording 13.7% organic year-on-year growth driven primarily by drug delivery system demand.The second driving factor is accelerating biosimilar launch volumes across adalimumab, trastuzumab, bevacizumab, and rituximab, which expand the pharmaceutical commercial demand base for prefilled syringe primary packaging.In May 2025, the FDA designated Samsung Bioepis and Organon's HADLIMA adalimumab-bwwd autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira across all presentations.The third driving factor is the reshoring of glass and polymer syringe manufacturing capacity to the United States, supported by federal production incentives.SCHOTT Pharma committed USD 371 Million to its first United States manufacturing plant, responding to reshoring policy incentives under Executive Order 14017.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single container manufacturing platform widens its addressable revenue every time it earns qualification for a new drug formulation on the same underlying glass or polymer barrel design, without the manufacturer having to build an entirely new production line from zero.Once a syringe barrel platform is validated and qualified for one biologic or GLP-1 fill-finish programme, extending that same platform to a new pharmaceutical customer's formulation adds incremental order volume without a new capital investment cycle, so container revenue compounds as the qualified formulation list grows around the original manufacturing line.As a result, demand and revenue share are concentrating around container platforms with the broadest formulation compatibility, including silicone oil-free and PFAS-free options for sensitive biologics, that hold the deepest pharmaceutical customer qualification base, and the forecast tilts toward these multi-formulation platforms rather than single-purpose container designs.For instance, in April 2025, Gerresheimer, Germany, partnered with Injecto to launch silicone-oil- and PFAS-free syringe systems, extending its existing container platforms to meet a formulation compatibility requirement that a growing share of biologics and ophthalmic drugs now demand, without a new barrel design programme.These are some of the key factors driving revenue growth of the market.

Because Novo Nordisk's oral semaglutide programme is in late-stage clinical development, this represents a mid-horizon demand substitution risk for injectable prefilled device manufacturers if oral formulations achieve comparable efficacy at commercially viable doses.

Polymer container cost is a second constraint, since cyclopolyolefin prefilled syringes carry higher per-unit costs than standard borosilicate glass and require dedicated fill-finish equipment validation, limiting polymer penetration to specialist applications.

Glass primary packaging inventory cycle variability is a third constraint, since destocking effects at pharmaceutical customers have measurably impacted glass container manufacturer revenue, confirming demand timing mismatches between pharmaceutical fill-finish planning cycles and glass container supply commitments.

These factors substantially limit disposable prefilled syringes market growth over the forecast period.

The clearest driver of demand is the commercial scale-up of GLP-1 receptor agonist therapies, which has already reshaped capital investment across the entire prefilled syringe supply chain. A therapy class only forces container manufacturer capacity expansion at this scale if patient volume growth outpaces existing qualified production lines, and GLP-1 volume has done exactly that, forcing both drugmakers and container suppliers to commit capital simultaneously rather than sequentially. Novo Nordisk and Eli Lilly have both reported manufacturing capacity expansions of over one-third for prefilled syringe and pen device production, with Eli Lilly's broader Lilly in America programme committing USD 27 Billion to US manufacturing footprint expansion. Stevanato Group expanded its ready-to-fill facility capacity by 25% in Italy during 2025, with GLP-1-related products accounting for approximately 19 to 20% of the company's 2025 revenue and growing more than 50% year over year. The effect on the market is that container manufacturer capacity investment is now a leading indicator of GLP-1 commercial trajectory, not a lagging response to it. These are some of the key factors driving revenue growth of the market.

The second driver is the reshoring of prefilled syringe container manufacturing to the United States, driven by both commercial demand and federal policy incentives. A container manufacturer only builds a first-ever US facility if the combination of demand certainty and policy incentive makes the multi-year capital commitment defensible, and SCHOTT Pharma's USD 371 Million Wilson, North Carolina facility, backed by Executive Order 14017 reshoring incentives, met exactly that bar. In June 2026, SCHOTT Pharma inaugurated a BARDA-funded expansion exceeding USD 60 Million at its Lebanon, Pennsylvania facility, adding new production lines for standard and sterile ready-to-use glass vials that strengthen US domestic medical supply chain resilience. Gerresheimer completed a EUR 100 Million expansion and modernisation of its Lohr site, installing a new oxy-hybrid glass furnace that increases production capacity while operating with up to 50% electricity and reducing CO2e emissions by up to 40%. The effect on the market is that US-based prefilled syringe capacity is expanding faster than global capacity overall, shifting the geographic centre of gravity for new container manufacturing investment toward North America. These are some of the key factors driving revenue growth of the market.

“Stevanato Group's GLP-1-related revenue grew more than 50% year over year in 2025, reaching approximately 19 to 20% of the company's total revenue from a category that barely existed in its portfolio five years earlier.”

However, the disposable prefilled syringes market faces severe adoption constraints from oral GLP-1 formulation development, polymer container cost premiums, and glass primary packaging inventory cycle variability.

Because Novo Nordisk's oral semaglutide programme is in late-stage clinical development and has already reached commercial launch in some markets, this represents a genuine mid-horizon demand substitution risk for injectable prefilled device manufacturers, even though industry executives currently expect injectable formats to remain the majority format through the decade.

Polymer container cost is a second constraint, since cyclopolyolefin prefilled syringe barrels carry higher per-unit costs than standard borosilicate glass and require dedicated fill-finish equipment validation, limiting COP adoption to specialist biologics and temperature-sensitive mRNA applications.

Glass primary packaging inventory cycle variability is the third constraint, since destocking effects at pharmaceutical customers have measurably impacted glass container manufacturer revenue even during periods of strong underlying therapy demand growth, confirming that inventory cycle timing, not just end demand, drives near-term container order volume.

These factors substantially limit disposable prefilled syringes market growth over the forecast period.

Based on regional analysis, the disposable prefilled syringes market in North America accounted for the largest revenue share in 2025. The United States drives the regional position through the deepest biologic pipeline globally, BD's 40% US capacity expansion programme, and SCHOTT Pharma's USD 371 Million first US manufacturing plant investment. The CDC documented 8.7 million US insulin users in 2024 consuming approximately 3.2 billion insulin syringe units annually, and Eli Lilly's Lilly in America programme has committed USD 27 Billion to US manufacturing footprint expansion. The concentration of GLP-1 commercial volume and reshoring investment in the United States also means new container manufacturing capacity is often built in the United States first.

The market in Europe is expected to register a steady revenue growth rate in the global disposable prefilled syringes market over the forecast period.

Germany, France, Italy, and the United Kingdom represent the four largest national prefilled syringe markets within Europe. Gerresheimer maintains the leading European prefillable glass syringe manufacturing position, and Novo Nordisk announced an investment exceeding USD 500 Million to expand capacity at its Athlone, Ireland site to support current and future GLP-1 treatments including the Wegovy pill. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have disrupted borosilicate glass tube supply chains, with an IMF assessment confirming approximately 20% disruption to global specialty materials trade flows affecting glass tube procurement costs at European syringe manufacturing facilities through 2026.

The market in Asia Pacific is expected to register a rapid revenue growth rate in the global disposable prefilled syringes market over the forecast period.

Japan, China, India, and South Korea represent the four largest national prefilled syringe markets within the region. Otsuka Pharmaceutical and NAMSA-Terumo partnerships confirm Japanese manufacturer strategy for accelerating global prefilled device market access, while Stevanato Group's continued investment in production capacity across its global footprint supports the region's fastest regional CAGR. Regional governments are fostering local manufacturing to address import deficits, leaving more structural room for capacity growth than in the already-reshoring North American market.

The market in Latin America is expected to register a moderate revenue growth rate in the global disposable prefilled syringes market over the forecast period.

Brazil and Mexico represent the two largest national disposable prefilled syringe markets within the region, with Brazil's expanding private healthcare sector and biologic medicine reimbursement through the Unified Health System creating demand for prefilled syringe formats in oncology, rheumatology, and diabetes care. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have maintained elevated component costs for prefilled syringe manufacturers supplying Brazilian distribution networks, a disruption that has run through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate in the global disposable prefilled syringes market over the forecast period.

Saudi Arabia and the United Arab Emirates represent the primary commercial markets within the GCC. Saudi Arabia is the most established market on the continent for biologic and GLP-1 prefilled device access, supported by the Vision 2030 healthcare investment programme, while the wider Gulf and North African sub-regions are still building the cold-chain and fill-finish infrastructure prefilled biologic distribution requires.